Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 28:14:1308343.
doi: 10.3389/fonc.2024.1308343. eCollection 2024.

Locoregional recurrence and survival of breast-conserving surgery compared to mastectomy following neoadjuvant chemotherapy in operable breast cancer

Fa-You Lv #  1 , Zongming Mo #  2 , Binjie Chen #  1 , Zhen Huang  1 , Qinguo Mo  1 , Qixing Tan  1
Affiliations

Locoregional recurrence and survival of breast-conserving surgery compared to mastectomy following neoadjuvant chemotherapy in operable breast cancer

Fa-You Lv et al. Front Oncol. .

Abstract

Background: The risk of locoregional recurrence (LRR) and the long-term prognosis of breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC) are still controversial. This study aimed to evaluate oncological outcomes for patients undergoing BCS after NAC and determine LRR and survival predictors.

Methods: This study was a retrospective cohort study of patients with locally advanced breast cancer (LABC) who received NAC and underwent BCS or mastectomy from June 2011 to November 2020. LRR, disease-free survival (DFS), and overall survival (OS) were compared in patients undergoing BCS or mastectomy. Univariate and multivariate analyses were performed to determine LRR, DFS, and OS predictors.

Results: A total of 585 patients were included, of whom 106 (18.1%) underwent BCS and 479 (81.9%) underwent a mastectomy. The LRR rate was 11.3% in the BCS group and 16.3% in the mastectomy group, revealing no significant difference(p = 0.200). In patients who underwent BCS, clinical lymph node status, histological grade and pathological complete response (pCR) were independent factors to predict LRR. There was no significant difference in DFS and OS between the BCS and the mastectomy groups. Multivariable analysis showed that lymph node status, histological grade, molecular subtypes, pCR and Miller&Payne (M&P) classification were independent predictors of DFS. Lymph node status, molecular subtypes and pCR were independent predictors of OS. BCS or mastectomy was not an independent predictor of DFS or OS.

Conclusion: Compared with mastectomy, BCS after NAC may not increase the risk of local recurrence or mortality, BCS can be performed in selected patients with small tumor size and good response to NAC.

Keywords: breast cancer; breast-conserving surgery; mastectomy; neoadjuvant chemotherapy; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of study selection process. T, tumor stage; N, nodal stage; M, metastasis; NAC, Neoadjuvant chemotherapy.
Figure 2
Figure 2
Disease−free survival in the BCS group compared with the mastectomy group.
Figure 3
Figure 3
Overall survival in the BCS group compared with the mastectomy group.
Figure 4
Figure 4
Adjusted survival functions for disease-free survival by type of breast surgery.
Figure 5
Figure 5
Adjusted survival functions for overall survival by type of breast surgery.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. (2019) 144:1941–53. doi: 10.1002/ijc.31937 - DOI - PubMed
    1. Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JF. Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol. (2009) 35:113–22. doi: 10.1016/j.ejso.2008.03.015 - DOI - PubMed
    1. Chen C, Sun S, Yuan JP, Wang YH, Cao TZ, Zheng HM, et al. . Characteristics of breast cancer in Central China, literature review and comparison with USA. Breast. (2016) 30:208–13. doi: 10.1016/j.breast.2016.01.004 - DOI - PubMed
    1. Franceschini G, Terribile D, Fabbri C, Magno S, D’Alba P, Chiesa F, et al. . Management of locally advanced breast cancer. Mini-review. Minerva Chir. (2007) 62:249–55. - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) . Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomized trials. Lancet Oncol. (2018) 19:27–39. doi: 10.1016/s1470-2045(17)30777-5 - DOI - PMC - PubMed

LinkOut - more resources